LONDON (Alliance News) - Abzena PLC Thursday said its subsidiary, Antitope Ltd, has entered into a research and licence agreement with University College London to humanize an antibody to promote the growth of blood vessels in cancer patients.
The collaboration to humanize an anti-LRG1 antibody is part of a MRC-funded translational research and product development programme being undertaken by the UCL Institute of Ophthalmology.
Abzena, the life sciences company, said that LRG1 was identified by researchers at University College London to promote the growth of blood vessels.
In a statement, Abzena said its subsidiary, Antitope, will produce a range of fully humanized antibodies using its Composite Human Antibody technology.
"The use of antagonists of LRG1 to inhibit angiogenesis is an interesting area of research that could lead to the treatment of a number of different angiogenesis-driven diseases such as AMD and some cancers. We are delighted to be supporting UCL in the development of a fully human anti-LRG1 antibody," said Abzena Chief Scientific Officer Matt Baker in a statement.
Abzena shares closed flat Thursday at 81.00 pence.
By Rowena Harris-Doughty; rowenaharrisdoughty@alliancenews.com; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
